Giovanni Tonon

Early tolerance and late persistence as alternative drug responses in cancer

UNCAN.eu: Toward a European Federated Cancer Research Data Hub

Clinical bioinformatics desiderata for molecular tumor boards

Cancer Evolution: A Multifaceted Affair

Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection

Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation

Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells

Disentangling the microRNA regulatory<i>milieu</i>in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients

Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia

Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers

Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128–350 triggers MM cell death via c-Jun upregulation

Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1128–350 Triggers MM Cell Death Via c- Jun Upregulation